Opendata, web and dolomites

RSVTriVax SIGNED

Development of a trivalent epitope-focused RSV vaccine to boost pre-existing immunity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RSVTriVax project word cloud

Explore the words cloud of the RSVTriVax project. It provides you a very rough idea of what is the project "RSVTriVax" about.

elderly    health    stable    formulation    competitor    pregnant    ve    globally    infants    neutralizing    superior    epitopes    molecular    viral    exquisite    functional    world    virus    33    promise    emerge    sophisticated    cohort    epitope    manufacturing    model    syncytial    elicited    scenario    neutralization    close    prevent    intensive    children    young    boost    tools    attributed    deemed    financial    primates    strongest    showed    protective    cocktail    mimicking    molecules    animal    annually    carries    women    primary    candidates    boosting    subdominant    societal    respiratory    natural    120    rsv    human    organization    decades    antibodies    suggesting    global    competitive    burdens    infection    clinically    alternative    candidate    trivax    immunogens    induction    vaccine    infections    cutting    safety    preliminary    public    episodes    eliciting    approved    immune    deaths    potent    causes    populations    yield    protect    good    mostly    mechanisms    profile    pathogen    abs    thereby    million    edge    consolidate    commercial    compelling    na    protection    iuml   

Project "RSVTriVax" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 150˙000.00

Map

 Project objective

The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most affected populations are pre-term infants, young children and the elderly. Several decades of intensive research are yet to yield a clinically approved vaccine. This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective antibodies (Abs). Using cutting-edge molecular design tools, we developed a novel vaccine candidate (TriVax) to focus immune responses in such key neutralization epitopes. TriVax is a cocktail composed of three epitope-focused immunogens mimicking three distinct neutralization epitopes targeted by potent neutralizing Abs. Our primary target populations are pregnant women (protection of pre-term infants) and elderly, where the challenge is to boost subdominant, neutralizing Abs elicited during previous natural infections. Recently, we showed that epitope-focused immunogens are exquisite at boosting subdominant functional Abs, and in this scenario, superior to the strongest competitor vaccine candidates. In a preliminary study in Non-Human Primates, TriVax showed great promise by eliciting robust neutralization on an RSV naïve cohort, suggesting a good safety profile and the potential to emerge as a competitive alternative for vaccine development. For manufacturing, epitope-focused immunogens are simple and stable molecules that can be produced at low cost. Overall, we propose a viable vaccine formulation to protect against an important pathogen which carries large financial burdens on public health systems. Thus, our proposal has an important societal and financial impact, and will provide compelling evidence for Trivax to boost neutralizing Abs in a close-to-human animal model, thereby taking an essential step to consolidate the commercial potential of our vaccine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RSVTRIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RSVTRIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

Malaria POC (2019)

Ultrasensitive detection of transmissible malaria

Read More  

TALNET (2020)

Transparent Aluminium Networks

Read More